drug_type
RELEVANT_DRUG
intervention_type
Antibody-Drug Conjugate (Biological)
drug_description
A HER3 (ERBB3)-targeted antibody–drug conjugate administered IV every 3 weeks. The monoclonal antibody binds HER3 on tumor cells, is internalized, and releases a cytotoxic payload to kill HER3-expressing cells; by engaging HER3-containing ERBB dimers (HER3–EGFR, HER3–HER2), it suppresses downstream PI3K–AKT/MAPK signaling.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Antibody-Drug Conjugates
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
HER3-targeted monoclonal antibody–drug conjugate that binds ERBB3 on tumor cells, is internalized, and releases a cytotoxic payload to kill HER3-expressing cells; by engaging HER3-containing ERBB dimers (HER3–EGFR/HER3–HER2), it suppresses downstream PI3K–AKT/MAPK signaling.
drug_name
SYS6023
nct_id_drug_ref
NCT07110883